Zydus Therapeutics Inc.
Clinical trials sponsored by Zydus Therapeutics Inc., explained in plain language.
US subsidiary of Zydus Lifesciences, developing pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Liver drug study seeks to understand how body processes medication in scarred livers Results expected Dec 2026 (estimated)
- New drug study aims to understand how liver disease affects medication Results expected Dec 2026 (estimated)
- Hope for liver disease: new drug trial targets PBC symptoms Results expected Apr 2027 (estimated)
-
New hope for PBC patients: phase 3 trial of saroglitazar launches
Disease control Recruiting nowThis study tests a new drug, saroglitazar magnesium, in 89 adults with primary biliary cholangitis (PBC) who did not get enough benefit from or could not tolerate standard treatment (UDCA). The goal is to see if the drug can lower a key liver enzyme (alkaline phosphatase) to norm…
Phase 3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New ALS drug usnoflast enters key trial to slow deadly disease
Disease control Recruiting nowThis study tests whether the drug usnoflast can slow the progression of ALS, a severe nerve disease that causes muscle weakness and breathing problems. About 240 adults with ALS will receive either usnoflast or a placebo for 36 weeks. Researchers will measure changes in daily fun…
Phase 2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for rare liver disease: drug aims to slow damage
Disease control Recruiting nowThis long-term study tests whether saroglitazar magnesium can prevent serious liver complications in people with primary biliary cholangitis (PBC), a rare autoimmune liver disease. About 386 adults already on standard treatment will receive either the drug or a placebo. The goal …
Phase 3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Liver drug study seeks to understand how body processes medication in scarred livers
Knowledge-focused Recruiting nowThis study looks at how the drug Saroglitazar is processed in people with mild, moderate, or severe liver scarring (cirrhosis) caused by cholestatic liver disease. About 30 adults will take the drug once daily for 28 days. The goal is to measure drug levels in the blood and check…
Phase 1 • Sponsor: Zydus Therapeutics Inc. • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
New drug study aims to understand how liver disease affects medication
Knowledge-focused Recruiting nowThis early-stage study will test a drug called saroglitazar magnesium in 6 adults with moderate liver scarring (cirrhosis) caused by cholestatic liver disease. The main goal is to see how the drug moves through the body and if it is safe when taken every other day. Participants w…
Phase 1 • Sponsor: Zydus Therapeutics Inc. • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC